SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
MARCH 10, 2000
CUBIST PHARMACEUTICALS, INC
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-21379 22-3192085
- --------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
24 EMILY STREET, CAMBRIDGE, MASSACHUSETTS 02139
---------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (617) 576-1999
-2-
ITEM 5. OTHER EVENTS.
On March 10, 2000, the Registrant announced that it has filed a
Registration Statement with the Securities and Exchange Commission in connection
with its proposed public offering of 2,500,000 shares of Common Stock, which is
described in the Registrant's press release dated March 10, 2000, a copy of
which is filed as Exhibit 99.1 to this Report.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) EXHIBITS.
99.1 Press Release dated March 10, 2000
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CUBIST PHARMACEUTICALS, INC.
By: /s/ Thomas A. Shea
-----------------------------------
Thomas A. Shea
Vice President, Finance and
Administration, Treasurer and Chief
Financial Officer
Dated: March 14, 2000